HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

galactoxyloglucan

Networked: 12 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Polysaccharides: 15383
  - Glucans: 1624
    - galactoxyloglucan: 12
- Sugars: 11126
  - Monosaccharides: 889
    - Hexoses: 549
      - Galactose: 3212
        galactoxyloglucan: 12
Macromolecular Substances: 97
- Polymers: 13051
  - Biopolymers: 773
    - Glucans: 1624
      - galactoxyloglucan: 12

Experts

1.	Joseph, Manu M: 10 articles (02/2021 - 04/2014)
2.	Sreelekha, T T: 8 articles (02/2021 - 04/2014)
3.	Aravind, S R: 5 articles (02/2021 - 04/2014)
4.	George, Suraj K: 5 articles (02/2021 - 04/2014)
5.	Mini, S: 4 articles (02/2021 - 04/2014)
6.	Pillai, Raveendran K: 3 articles (02/2021 - 10/2014)
7.	Preethi, G U: 3 articles (01/2021 - 03/2017)
8.	Shiji, R: 3 articles (01/2021 - 03/2017)
9.	Unnikrishnan, B S: 3 articles (01/2021 - 03/2017)
10.	Maiti, Kaustabh Kumar: 2 articles (12/2017 - 06/2017)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2015 - "TRAIL-based tumor sensitizing galactoxyloglucan, a novel entity for targeting apoptotic machinery." 11/01/2014 - "Galactoxyloglucan-modified nanocarriers of doxorubicin for improved tumor-targeted drug delivery with minimal toxicity." 12/11/2017 - "In this strategy, a robust and ecofriendly green chemistry approach was adopted to construct galactoxyloglucan (PST001) endowed AuNPs (PST-GNPs) with cancer-cell-selective toxic nature and excellent biocompatibility. " 12/11/2017 - "Plasmonically Enhanced Galactoxyloglucan Endowed Gold Nanoparticles Exposed Tumor Targeting Biodistribution Envisaged in a Surface-Enhanced Raman Scattering Platform." 06/14/2017 - "Exploration of Biogenic Nano-chemobiotics Fabricated by Silver Nanoparticle and Galactoxyloglucan with an Efficient Biodistribution in Solid Tumor Investigated by SERS Fingerprinting."
2.	Dry Eye Syndromes (Dry Eye Syndrome) 01/01/2020 - "Improved Tear Film Stability in Patients with Dry Eye After Hyaluronic Acid and Galactoxyloglucan Use." 01/01/2020 - "We aimed to evaluate whether a preservative-free combination of 0.4% hyaluronic acid and 0.2% galactoxyloglucan can improve dry eye using the new topographer, Keratograph 5M. " 01/01/2020 - "A combination of 0.4% hyaluronic acid and 0.2% galactoxyloglucan artificial tears seems effective for treating dry eye. "
3.	Ascites 02/01/2021 - "Corrigendum to ``Co-encapsulation of doxorubicin with galactoxyloglucan nanoparticles for intracellular tumor-targeted delivery in murine ascites and solid tumors'' [Translational Oncology 7 (2014), 525-536]." 10/01/2014 - "Co-encapsulation of Doxorubicin with galactoxyloglucan nanoparticles for intracellular tumor-targeted delivery in murine ascites and solid tumors." 04/01/2014 - "Antitumor activity of galactoxyloglucan-gold nanoparticles against murine ascites and solid carcinoma."
4.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 03/01/2017 - "The use of biopolymers like galactoxyloglucan (PST001) for the fabrication of imatinib mesylate nanoparticles could impart its use in overcoming multidrug resistance in chronic myelogenous leukemia patients with minimal side effects. "
5.	Lung Neoplasms (Lung Cancer) 09/01/2019 - "Overcoming drug-resistance in lung cancer cells by paclitaxel loaded galactoxyloglucan nanoparticles."

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Lubricant Eye Drops (Artificial Tears)
3.	Hyaluronic Acid (Hyaluronan)
4.	PST001
5.	Gold
6.	Paclitaxel (Taxol)
7.	Silver
8.	Polysaccharides (Glycans)
9.	Folic Acid (Vitamin M)
10.	Biopolymers (Biopolymer)